Giralt S, Kantarjian H, Talpaz M
Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Semin Hematol. 1995 Apr;32(2):152-8.
INF-alpha therapy has been a major development in the treatment of CML. Maturing experience has confirmed its ability to induce durable major cytogenetic remissions, which translate into durable long-term disease control, and change in the natural history of the disease. Future studies aimed at improving the percentage and quality of cytogenetic remissions by combining INF-alpha therapy with other chemotherapeutic agents and/or biologicals are needed. The goal would be to identify strategies that can consistently achieve a major cytogenetic response rate of 40% to 50% in the general community setting with acceptable morbidity. Continued studies of the interactions between INF -alpha therapy and transplant strategies will permit the optimization of treatment for each individual patient with CML.
α-干扰素治疗一直是慢性粒细胞白血病治疗中的一项重大进展。不断积累的经验证实了它诱导持久的主要细胞遗传学缓解的能力，这转化为持久的长期疾病控制，并改变了疾病的自然病程。未来需要开展研究，将α-干扰素治疗与其他化疗药物和/或生物制剂联合使用，以提高细胞遗传学缓解的百分比和质量。目标是确定在一般社区环境中能够持续实现40%至50%的主要细胞遗传学缓解率且发病率可接受的策略。对α-干扰素治疗与移植策略之间相互作用的持续研究将有助于优化每位慢性粒细胞白血病患者的治疗。
